Cumberland Pharmaceuticals
Inc. CPIX today announced it has entered into an exclusive agreement
with Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the
registration and commercialization of Caldolor® (ibuprofen) Injection, which
is used to treat pain and fever in the hospital setting.
Under the terms of the agreement, SOHO receives an exclusive license to
Caldolor for the Indonesian market. SOHO will be responsible for seeking
regulatory approval, ongoing regulatory reporting, product marketing,
distribution and sales in the territory following approval. Cumberland
maintains responsibility for the intellectual property, product formulation,
manufacturing and other supported activities. In exchange for the license to
the product, Cumberland will receive upfront and milestone licensing payments,
as well as transfer prices on future sales of the drug.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in